BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

Molecular Cell

Volumn 51, Issue 6, 2013, Pages 751-765

  Sarosiek, KristopherA ^a,b   Chi, Xiaoke ^c   Bachman, JohnA ^b   Sims, JoshuaJ ^b   Montero, Joan ^a,b   Patel, Luv ^a,b   Flanagan, Annabelle ^a   Andrews, DavidW ^c   Sorger, Peter ^b   Letai, Anthony ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; DNA TOPOISOMERASE INHIBITOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE PERMEABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; HELA CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; OLIGOMERIZATION; OVERALL SURVIVAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TREATMENT RESPONSE; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MEMBRANE PROTEINS; MITOCHONDRIA; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; TOPOISOMERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84884548705     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.08.048     Document Type: Article

References (60)

1. Adachi M., Suematsu S., Kondo T., Ogasawara J., Tanaka T., Yoshida N., Nagata S. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 1995, 11:294-300.
2. Baldwin E.L., Osheroff N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 2005, 5:363-372.
3. Biswas S.C., Greene L.A. Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J.Biol. Chem. 2002, 277:49511-49516.
4. Bossy-Wetzel E., Newmeyer D.D., Green D.R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 1998, 17:37-49.
5. Bouillet P., Metcalf D., Huang D.C., Tarlinton D.M., Kay T.W., Köntgen F., Adams J.M., Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.
6. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
7. Cartron P.F., Juin P., Oliver L., Martin S., Meflah K., Vallette F.M. Nonredundant role of Bax and Bak in Bid-mediated apoptosis. Mol. Cell. Biol. 2003, 23:4701-4712.
8. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
9. Czabotar P.E., Westphal D., Dewson G., Ma S., Hockings C., Fairlie W.D., Lee E.F., Yao S., Robin A.Y., Smith B.J., et al. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 2013, 152:519-531.
10. Dansen T.B., Whitfield J., Rostker F., Brown-Swigart L., Evan G.I. Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression invivo. J.Biol. Chem. 2006, 281:10890-10895.
11. Davids M.S., Deng J., Wiestner A., Lannutti B.J., Wang L., Wu C.J., Wilson W.H., Brown J.R., Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012, 120:3501-3509.
12. Degenhardt K., Sundararajan R., Lindsten T., Thompson C., White E. Bax and Bak independently promote cytochrome C release from mitochondria. J.Biol. Chem. 2002, 277:14127-14134.
13. Deng J., Carlson N., Takeyama K., Dal Cin P., Shipp M., Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12:171-185.
14. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA 2004, 101:6164-6169.
15. Eischen C.M., Roussel M.F., Korsmeyer S.J., Cleveland J.L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 2001, 21:7653-7662.
16. Farrow S.N., White J.H., Martinou I., Raven T., Pun K.T., Grinham C.J., Martinou J.C., Brown R. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995, 374:731-733.
17. Ferreira C.G., Span S.W., Peters G.J., Kruyt F.A., Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2000, 60:7133-7141.
18. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 1996, 2:574-577.
19. Fuchs Y., Steller H. Programmed cell death in animal development and disease. Cell 2011, 147:742-758.
20. Fulda S., Strauss G., Meyer E., Debatin K.M. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic Tcells. Blood 2000, 95:301-308.
21. Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., Tu H.-C., Kim H., Cheng E.H.-Y., Tjandra N., Walensky L.D. BAX activation is initiated at a novel interaction site. Nature 2008, 455:1076-1081.
22. Handrick R., Ontikatze T., Bauer K.-D., Freier F., Rübel A., Dürig J., Belka C., Jendrossek V. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol. Cancer Ther. 2010, 9:2497-2510.
23. Hao C., Song J.H., Hsi B., Lewis J., Song D.K., Petruk K.C., Tyrrell D.L.J., Kneteman N.M. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 2004, 64:8502-8506.
24. Hikita H., Takehara T., Kodama T., Shimizu S., Shigekawa M., Hosui A., Miyagi T., Tatsumi T., Ishida H., Li W., et al. Delayed-onset caspase-dependent massive hepatocyte apoptosis upon Fas activation in Bak/Bax-deficient mice. Hepatology 2011, 54:240-251.
25. Hsu Y.-T., Youle R.J. Nonionic detergents induce dimerization among members of the Bcl-2 family. J.Biol. Chem. 1997, 272:13829-13834.
26. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell 1997, 88:347-354.
27. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
28. Kaina B. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem. Pharmacol. 2003, 66:1547-1554.
29. Kamer I., Sarig R., Zaltsman Y., Niv H., Oberkovitz G., Regev L., Haimovich G., Lerenthal Y., Marcellus R.C., Gross A. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 2005, 122:593-603.
30. Katz C., Zaltsman-Amir Y., Mostizky Y., Kollet N., Gross A., Friedler A. Molecular basis of the interaction between proapoptotic truncated BID (tBID) protein and mitochondrial carrier homologue 2 (MTCH2) protein: key players in mitochondrial death pathway. J.Biol. Chem. 2012, 287:15016-15023.
31. Kiefer M.C., Brauer M.J., Powers V.C., Wu J.J., Umansky S.R., Tomei L.D., Barr P.J. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995, 374:736-739.
32. Kim H., Rafiuddin-Shah M., Tu H.-C., Jeffers J.R., Zambetti G.P., Hsieh J.J.-D., Cheng E.H.-Y. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 2006, 8:1348-1358.
33. Kim H., Tu H.-C., Ren D., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J.-D., Cheng E.H.-Y. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 2009, 36:487-499.
34. Knudson C.M., Tung K.S., Tourtellotte W.G., Brown G.A., Korsmeyer S.J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995, 270:96-99.
35. Korsmeyer S.J., Wei M.C., Saito M., Weiler S., Oh K.J., Schlesinger P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7:1166-1173.
36. Krajewski S., Krajewska M., Reed J.C. Immunohistochemical analysis of invivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res. 1996, 56:2849-2855.
37. Leshchiner E.S., Braun C.R., Bird G.H., Walensky L.D. Direct activation of full-length proapoptotic BAK. Proc. Natl. Acad. Sci. USA 2013, 110:E986-E995.
38. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
39. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
40. Lindsten T., Ross A.J., King A., Zong W.X., Rathmell J.C., Shiels H.A., Ulrich E., Waymire K.G., Mahar P., Frauwirth K., et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 2000, 6:1389-1399.
41. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
42. Maas C., de Vries E., Tait S.W.G., Borst J. Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53. Oncogene 2011, 30:3636-3647.
43. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore V.D.G., Deng J., Anderson K.C., Richardson P., Tai Y.T., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
44. O'Connor L., Strasser A., O'Reilly L.A., Hausmann G., Adams J.M., Cory S., Huang D.C. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998, 17:384-395.
45. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
46. Sarosiek K.A., Nechushtan H., Lu X., Rosenblatt J.D., Lossos I.S. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. Br. J. Haematol. 2009, 147:308-318.
47. Sarosiek K.A., Malumbres R., Nechushtan H., Gentles A.J., Avisar E., Lossos I.S. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 2010, 115:570-580.
48. Shamas-Din A., Bindner S., Zhu W., Zaltsman Y., Campbell C., Gross A., Leber B., Andrews D.W., Fradin C. tBid undergoes multiple conformational changes at the membrane required for Bax activation. J. Biol. Chem. 2013, 288:22111-22127.
49. Slee E.A., Keogh S.A., Martin S.J. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ. 2000, 7:556-565.
50. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol. 2000, 20:3977-3987.
51. Tait S.W.G., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 2010, 11:621-632.
52. Vo T.-T., Ryan J., Carrasco R., Neuberg D., Rossi D.J., Stone R.M., Deangelo D.J., Frattini M.G., Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012, 151:344-355.
53. von Haefen C., Gillissen B., Hemmati P.G., Wendt J., Güner D., Mrozek A., Belka C., Dörken B., Daniel P.T. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004, 23:8320-8332.
54. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., Thompson C.B., Korsmeyer S.J. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000, 14:2060-2071.
55. Werner A.B., Tait S.W.G., de Vries E., Eldering E., Borst J. Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. J.Biol. Chem. 2004, 279:28771-28780.
56. Yamada H., Tada-Oikawa S., Uchida A., Kawanishi S. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem. Biophys. Res. Commun. 1999, 265:130-133.
57. Yin X.M., Wang K., Gross A., Zhao Y., Zinkel S., Klocke B., Roth K.A., Korsmeyer S.J. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999, 400:886-891.
58. Zaltsman Y., Shachnai L., Yivgi-Ohana N., Schwarz M., Maryanovich M., Houtkooper R.H., Vaz F.M., De Leonardis F., Fiermonte G., Palmieri F., et al. MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat. Cell Biol. 2010, 12:553-562.
59. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992.
60. Zinkel S.S., Hurov K.E., Ong C., Abtahi F.M., Gross A., Korsmeyer S.J. A role for proapoptotic BID in the DNA-damage response. Cell 2005, 122:579-591.